{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:33:56Z","timestamp":1793223236900,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010443","name":"RACP Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010443","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#2033081"],"award-info":[{"award-number":["#2033081"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.atherosclerosis.2026.121916","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:19:44Z","timestamp":1790954384000},"page":"121916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inflammation and lipoprotein(a) as predictors of cardiovascular events across baseline risk levels \u2013 results from the UK Biobank"],"prefix":"10.1016","volume":"422","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-4331","authenticated-orcid":false,"given":"Bradley","family":"Tucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-7614","authenticated-orcid":false,"given":"Kwok Leung","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5530-3717","authenticated-orcid":false,"given":"Thomas","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0213-7652","authenticated-orcid":false,"given":"Kristy P.","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-9136","authenticated-orcid":false,"given":"Anthony","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2739-9448","authenticated-orcid":false,"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.121916_bib1","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"group","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib2","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, Lipoprotein(a), and 30-Year cardiovascular outcomes in women","volume":"391","author":"Ridker Paul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and Anti-Interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib5","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein","volume":"359","author":"Ridker Paul","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib7","article-title":"The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease - a systematic review and meta-analysis","author":"Tucker","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib8","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jama.2018.8359","article-title":"Risk assessment for cardiovascular disease with nontraditional risk factors: US preventive services task force recommendation statement","volume":"320","author":"Force","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117437","article-title":"Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK biobank","volume":"389","author":"Welsh","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-Reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.124.071269","volume":"151","author":"Steg","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib14","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jacc.2023.05.035","article-title":"C-Reactive protein and risk of incident heart failure in patients with cardiovascular disease","volume":"82","author":"Burger Pascal","year":"2023","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib18","series-title":"Biomarker project companion document","author":"Biobank","year":"2019"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib19","series-title":"Algorithmically-defined outcomes","author":"Biobank","year":"2022"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023188","article-title":"Causes of death in people with cardiovascular disease: a UK biobank cohort study","volume":"10","author":"Drozd","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/eurjpc\/zwad187","article-title":"Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2","volume":"30","author":"Hageman","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","article-title":"Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use","volume":"1","author":"Heidari","year":"2016","journal-title":"Res Integrity Peer Rev"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib23","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.jcin.2020.09.024","article-title":"Prognostic impact of high-sensitivity C-Reactive protein in patients undergoing percutaneous coronary intervention according to BMI","volume":"13","author":"Beyhoff","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib24","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1093\/eurheartj\/ehaf281","article-title":"Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events","volume":"46","author":"Markus","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v111.i09","article-title":"How to interpret statistical models using marginaleffects for R and python","volume":"111","author":"Arel-Bundock","year":"2024","journal-title":"J Stat Software"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease","volume":"82","author":"Nelson","year":"2023","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib28","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of Lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/heartjnl-2023-323722","article-title":"Sex differences in the intensity of statin prescriptions at initiation in a primary care setting","volume":"110","author":"Kiss","year":"2024","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib34","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circulation: Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib35","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1093\/eurheartj\/ehaf209","article-title":"Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-norfolk study","volume":"46","author":"Kraaijenhof","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib36","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2025.08.101","article-title":"Association of Lipoprotein(a) and Interleukin-6 with cardiovascular risk: MESA and UK biobank","volume":"86","author":"Bhatia","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.121916_bib37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","article-title":"Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER study","volume":"55","author":"Glynn","year":"2009","journal-title":"Clin Chem"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026012827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:04:04Z","timestamp":1793221444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026012827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S0021915026012827"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121916","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation and lipoprotein(a) as predictors of cardiovascular events across baseline risk levels \u2013 results from the UK Biobank","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.121916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121916"}}